McIntyre C J, Allen J L Y, Constantinides V A, Jackson J E, Tolley N S, Palazzo F F
Hammersmith Hospital, Imperial College Healthcare NHS Trust , UK.
Imperial College London , UK.
Ann R Coll Surg Engl. 2015 Nov;97(8):598-602. doi: 10.1308/rcsann.2015.0039. Epub 2015 Oct 7.
Reoperative parathyroidectomy is required when there is persistent or recurrent hyperparathyroidism following the initial surgery (at least 5% of parathyroidectomies nationally). By convention, 'persistent disease' is defined as the situation where the patient has not been cured by the first operation. The term 'recurrent hyperparathyroidism' is used when the patient was confirmed to be biochemically cured for six months from the first operation but has hyperparathyroidism after this date. Reoperative surgery is associated with higher rates of postoperative complications as well as a greater rate of failure to cure. The aim of our study was to review our departmental experience of reoperative parathyroidectomy, with a view to identify patterns of disease persistence and recurrence.
Using a departmental database, patients were identified who had undergone reoperative parathyroidectomy between 2006 and 2014. All the pre, intra and postoperative information was documented including the operative note so as to record the location of the abnormal parathyroid gland found at reoperation.
Almost two-thirds (63%) of patients had negative, equivocal or discordant conventional imaging so secondary investigative tools were required frequently. The majority of abnormal glands were found in eutopic locations. The most common locations for ectopic glands were intrathyroidal, mediastinal and intrathymic. A third (33%) of the patients had multigland disease and over a quarter (28%) had coexisting thyroid disease.
Persistent hyperparathyroidism represents a challenging patient subgroup for which access to all radiological modalities and intraoperative parathyroid hormone monitoring are required. Patient selection for reintervention is a key determinant in the reoperation cure rate.
当初次手术后出现持续性或复发性甲状旁腺功能亢进时,需要进行再次甲状旁腺切除术(在全国范围内,至少5%的甲状旁腺切除术属于这种情况)。按照惯例,“持续性疾病”定义为患者首次手术未治愈的情况。“复发性甲状旁腺功能亢进”一词用于指患者在首次手术后经生化检查确认已治愈6个月,但此后又出现甲状旁腺功能亢进的情况。再次手术与更高的术后并发症发生率以及更高的治疗失败率相关。我们研究的目的是回顾我们科室再次甲状旁腺切除术的经验,以确定疾病持续和复发的模式。
利用科室数据库,确定2006年至2014年间接受再次甲状旁腺切除术的患者。记录所有术前、术中和术后信息,包括手术记录,以便记录再次手术时发现的异常甲状旁腺的位置。
近三分之二(63%)的患者传统影像学检查结果为阴性、不明确或不一致,因此经常需要使用二级检查工具。大多数异常腺体位于正常位置。异位腺体最常见的位置是甲状腺内、纵隔和胸腺内。三分之一(33%)的患者有多发性腺体疾病,超过四分之一(28%)的患者合并甲状腺疾病。
持续性甲状旁腺功能亢进是一个具有挑战性的患者亚组,对于该亚组患者,需要使用所有放射学检查方法并进行术中甲状旁腺激素监测。再次干预的患者选择是再次手术治愈率的关键决定因素。